Open AccessLopinavir Exposure With an Increased Dose During Pregnancy
Author(s) -
Mark Mirochnick,
Brookie M. Best,
Alice Stek,
Edmund V. Capparelli,
Chengcheng Hu,
Sandra Burchett,
Diane T. Holland,
Elizabeth Smith,
Sreedhar Gaddipati,
Jennifer S. Read
Publication year - 2008
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318186edd0
Subject(s) - lopinavir , medicine , lopinavir/ritonavir , pharmacokinetics , pregnancy , dosing , ritonavir , third trimester , prospective cohort study , area under the curve , obstetrics , gestation , viral load , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , immunology , biology , genetics
Use of standard adult lopinavir/ritonavir (LPV/RTV) dosing (400/100 mg) during the third trimester of pregnancy results in reduced LPV exposure. The goal of this study was to determine LPV exposure during the third trimester of pregnancy and 2 weeks postpartum with a higher LPV/RTV dose.